Eli Lilly’s Kisunla™ (Donanemab) Approved by China’s NMPA for Early Symptomatic Alzheimer’s Disease

Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) in China has approved Kisunla...

December 18, 2024 | Wednesday | News
Sanofi and Teva’s Duvakitug Achieves Key Milestones in Phase 2b Study for Ulcerative Colitis and Crohn’s Disease

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endp...

December 18, 2024 | Wednesday | News
Merck Announces FDA Acceptance of BLA for Clesrovimab (MK-1654), Investigational Monoclonal Antibody for Infant RSV Prevention

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics L...

December 18, 2024 | Wednesday | News
Microbio’s MS-20 Combined with Keytruda Shows Promising Results in Advanced Lung Cancer Trial

Microbio Co., Ltd. (4128)  revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage II...

December 17, 2024 | Tuesday | News
EMA Committee Issues Positive Opinion for Long-Acting HIV Treatment Vocabria + Rekambys for Adolescents

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, ...

December 17, 2024 | Tuesday | News
Merck Discontinues Clinical Development of Vibostolimab and Favezelimab in Oncology Trials

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programs for vibostolima...

December 17, 2024 | Tuesday | News
Menarini, Stemline, and MEDSIR Unveil Groundbreaking ADELA Trial for Advanced ER+/HER2- Breast Cancer at SABCS 2024

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...

December 16, 2024 | Monday | News
Eli Lilly's Omvoh® (Mirikizumab) Receives Positive CHMP Opinion for Crohn’s Disease in the EU

Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

December 16, 2024 | Monday | News
Merck’s WELIREG® Receives Positive CHMP Opinion for VHL Disease-Associated Tumors and Advanced RCC in the EU

Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...

December 16, 2024 | Monday | News
Accropeutics' RIPK2 Inhibitor AC-101 Receives FDA Clearance for Phase II Trial in Ulcerative Colitis

Accropeutics Inc. (Accropeutics), a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in...

December 16, 2024 | Monday | News
A2A Pharmaceuticals Advances Phase 1 Clinical Trial of TACC3 Inhibitor A0-252 in Ovarian, TNBC, and Endometrial Cancers

A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies,...

December 13, 2024 | Friday | News
Imlunestrant Shows Significant PFS Improvement in Phase 3 EMBER-3 Trial for ER+ HER2- Advanced Breast Cancer

Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...

December 13, 2024 | Friday | News
FDA Grants Fast Track Designation to Sanofi’s Combination Vaccines for Influenza and COVID-19 in Older Adults

The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infec...

December 13, 2024 | Friday | News
AstraZeneca and Merck Announce Six-Year Data from OlympiA Trial, Showing LYNPARZA Significantly Improves Survival in BRCA-Mutated Early Breast Cancer

 AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced long-term results from the OlympiA Phase 3 trial w...

December 13, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close